Shots:

• Kadmon to receive ~$29M as development- regulatory & commercial milestones with royalties on sales of KD025 in Japan and certain other Asian countries
• The JV- named as Romeck Pharma has the HQ in Japan with shared oversight between Kadmon and Meiji
• KD025 is ROCK2 inhibitor with the potential to treat inflammatory and fibrotic diseases- being studies in a clinical study for cGVHD in the US & has received FDA’s BT designation for cGVHD following 2L+ systemic therapies

Click here to­ read full press release/ article | Ref: Kadmon | Image: Kadmon